Denifanstat is a drug designed to treat liver diseases like MASH and skin conditions like acne, but it works in a completely different way from antibiotics or retinoids. It targets an enzyme called fatty acid synthase, or FASN, which helps make fats in the body.[1][2][3][6]
Antibiotics fight infections by killing or stopping the growth of bacteria. They are common for acne because bacteria can play a role in causing pimples. Retinoids, on the other hand, come from vitamin A and work by speeding up skin cell turnover, unclogging pores, and reducing inflammation. Drugs like isotretinoin are powerful retinoids used for severe acne.[5]
Denifanstat does none of that. Instead, it blocks FASN, a protein that builds fatty acids in cells.[1][2][3][6] In the liver, this cuts down fat buildup, eases inflammation, and fights scarring in MASH, a condition where fat harms the liver and leads to fibrosis.[1][2] For acne, it lowers sebum production, the oily substance that clogs pores and causes breakouts, without touching bacteria or acting like vitamin A.[3][5]
Company tests show denifanstat is safe when taken as a daily pill, often paired with other drugs like resmetirom for better results in advanced liver fibrosis.[1][2] Early studies for moderate to severe acne also point to fewer lesions by tackling fat and inflammation directly.[3] This makes it a fresh option in fields hungry for non-antibiotic treatments, as overuse of antibiotics can lead to resistance.[5]
FASN is a natural human enzyme on chromosome 17, key for fat synthesis but not linked to bacterial killing or retinoid pathways.[6] By inhibiting it selectively, denifanstat avoids the side effects of antibiotics, like gut issues, or retinoids, like dry skin and birth defect risks.
Sources
https://www.barchart.com/story/news/36686639/sagimet-biosciences-announces-positive-results-from-the-phase-1-pk-clinical-trial-of-denifanstat-and-resmetirom-combination
https://www.globenewswire.com/news-release/2025/12/18/3207571/0/en/Sagimet-Biosciences-Announces-Positive-Results-from-the-Phase-1-PK-Clinical-Trial-of-Denifanstat-and-Resmetirom-Combination.html
https://www.dermatologyadvisor.com/news/denifanstat-improves-lesion-count-moderate-severe-acne-vulgaris/
https://markets.businessinsider.com/news/stocks/sagimet-biosciences-and-tapi-announce-global-license-agreement-for-innovative-forms-of-resmetirom-api-for-sagimet-s-fixed-dose-combination-program-1035652517
https://www.dermatologytimes.com/view/dermatology-times-2025-year-in-review-acne
https://www.ncbi.nlm.nih.gov/gene/2194
